Nivolumab does not improve survival in patients with advanced renal cell carcinoma with progression after immune checkpoint inhibitors
1. No significant difference was seen regarding progression-free survival between the tivozanib-nivolumab and tivozanib monotherapy groups. 2. Serious adverse events were comparable between both intervention groups. Evidence Rating Level: 1 (Excellent) Study...